Scott Alspach

Senior Oncology Sales Specialist at Takeda Oncology

Scott Alspach is a highly experienced Senior Oncology Sales Specialist at Takeda Oncology, focusing on leukemia management within New York City and its boroughs. With a career spanning over three decades in the oncology and pharmaceutical sectors, Scott has held significant roles at companies such as Prometheus Oncology, Eisai, MGI Pharma, and Aventis Pharmaceuticals. Responsibilities have included promoting various oncology products, conducting extensive training for healthcare professionals, and enhancing patient outcomes through strategic initiatives. Scott holds an MBA in Business Administration from Lehigh University and a BS in Business Finance from Albright College.

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Takeda Oncology

21 followers

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.


Employees

1,001-5,000

Links